Health ❯ Healthcare ❯ Clinical Trials

Cancer Treatment

Multiple Myeloma Prostate Cancer Breast Cancer Colorectal Cancer Head and Neck Cancer Survival Rates CAR T-cell Therapy Immunotherapy Targeted Therapies PARP Inhibitors Chronic Lymphocytic Leukemia Combination Therapy Immunotherapy Strategies Endocrine Therapy Intensity-Modulated Radiation Therapy CAR-NK Cells Immunotherapy Research Drug Development Pan-Cancer Therapies Neuroendocrine Tumors Proton Beam Therapy Endometrial Cancer Immune Response Therapeutic Vaccines Innovative Therapies Drug Resistance Patient Enrollment Bruton Tyrosine Kinase Inhibitors Drug Efficacy HER2-positive Breast Cancer Advanced Colorectal Cancer Immunotherapy Drugs Personalized Medicine Androgen Therapy Glioblastoma Trials Dormant Cells Targeted Therapy Triple-Negative Breast Cancer CAR-NK Therapy CAR-T Therapy Immunotherapeutics CAR-T Cell Efficacy Small Lymphocytic Lymphoma (SLL) AML Treatment Strategies FGFR2b-targeted Therapy Oropharyngeal Cancer EGFR-mutant NSCLC Ovarian Cancer Therapeutics Chronic Lymphocytic Leukemia (CLL) Radiation Therapy CAR T Therapy Gastrointestinal Cancers Pancreatic Ductal Adenocarcinoma (PDAC) Tumor Microenvironment Tandem CAR T-cells Personalized Therapy Acupuncture CAR-T Cell Therapy BRAF Mutation Solid Tumors

Erasca Shares Plunge After Trial Death and Patent Challenge

The drop highlights doubts that early ERAS-0015 data show a clear edge over Revolution Medicines' daraxonrasib.

Allogene Soars on Early ALPHA3 Readout Showing Strong MRD Edge and Clean Safety

Transgene Completes Phase 2 Randomization for Personalized Cancer Vaccine TG4050

Androgen Signaling Drives Lethal Pediatric Ependymoma, Study Finds

Ligand-Based OSM CAR-T Shows Preclinical Efficacy Against Osteosarcoma

ImmunityBio Sets 30-Day FDA Submission After Positive Meeting on Anktiva Expansion

Abemaciclib Shows Early Benefit Signal in Genetically Selected High-Grade Meningioma Trial

Acupuncture Improves Perceived Cognition With a Modest Memory Edge for Real Needling

Exicure’s Burixafor Delivers About 90% Stem-Cell Mobilization in Phase 2 as Shares Surge

Pirtobrutinib Extends First-Line PFS vs BR and Shows Higher Response Rates Than Ibrutinib in CLL/SLL

Early Cilta-Cel Use Linked to Better Outcomes in Relapsed/Refractory Myeloma, ASH 2025 Data Show

Kisqali Cuts Recurrence in 5-Year NATALEE Results for High-Risk Early HR+/HER2- Breast Cancer

Datroway Extends Survival Over Chemotherapy in First-Line TNBC Ineligible for Immunotherapy

Engineered CAR-T Cells Target PD-L1 to Deliver IL-12 at Tumors, Showing Solid-Tumor Gains in Mice

TORPEdO Phase III Finds No One-Year Advantage for Proton Therapy Over IMRT in Oropharyngeal Cancer

Glycan-Targeting ‘GlyTR’ Therapy Kills Diverse Cancers in Preclinical Tests

Engineered Salmonella Triggers Tumor Immune Hubs, Slows Colorectal Cancer in Mice

City of Hope Launches National Clinical Trial Network to Expand Access to Cancer Treatments

Jaypirca Delivers Significant PFS Benefit Over Chemoimmunotherapy in First-Line CLL/SLL

Iza-Bren Plus Osimertinib Delivers 100% Response in Small First-Line EGFR-Mutant NSCLC Cohort